Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effects of Different Doses of Caffeine on Physical and Cognitive Performance in Female Handball Players

24. april 2026 oppdatert av: Ulaş Can YILDIRIM, Sinop University

Dose-Dependent Effects of Acute Caffeine Ingestion on Physical and Cognitive Performance in Female Handball Players: A Randomized, Double-Blind, Placebo-Controlled Crossover Study

This study investigates how different doses of caffeine affect physical and cognitive performance in female handball players. Caffeine is widely used as a performance-enhancing substance, but its effects may vary depending on the type of performance and the dose consumed.

In this randomized, double-blind, placebo-controlled crossover study, participants complete three experimental conditions: placebo, low-dose caffeine (3 mg/kg), and moderate-dose caffeine (6 mg/kg). Each participant receives all conditions in a randomized order, with sufficient time between sessions to avoid carryover effects.

The study evaluates three main performance domains relevant to team sports. Physical performance is assessed using an intermittent running test. Cognitive performance is measured using a reaction time task that evaluates attention and inhibitory control. In addition, a throwing test is used to assess sport-specific motor performance.

The main objective is to determine whether caffeine produces dose-dependent improvements and whether these effects differ across physical, cognitive, and technical performance domains. The findings aim to provide practical insights for athletes and coaches regarding optimal caffeine use in team sport settings.

Studieoversikt

Detaljert beskrivelse

Caffeine is one of the most widely consumed ergogenic aids in sport, known to influence both physiological and cognitive processes primarily through antagonism of adenosine receptors. Although its beneficial effects on endurance performance and alertness are well established, evidence regarding its effects on cognitive control and sport-specific technical skills remains inconsistent, particularly in team sport settings where multiple performance domains interact.

Team sports such as handball require the integration of intermittent high-intensity physical efforts, rapid decision-making, and precise motor execution. These components are not independent; instead, they compete for shared neurocognitive resources, especially under conditions of fatigue. As a result, interventions such as caffeine supplementation may exert domain-specific effects rather than uniform improvements across all aspects of performance.

Despite extensive research on caffeine, most studies have examined either physical or cognitive outcomes in isolation. Furthermore, dose-response relationships remain unclear, with previous findings suggesting that lower doses may be sufficient to enhance physical performance, whereas cognitive outcomes may require higher levels of stimulation. However, limited evidence exists on whether these dose-dependent effects are maintained when multiple performance domains are assessed within the same experimental framework.

The present study addresses this gap by simultaneously evaluating physical, cognitive, and sport-specific motor performance following different doses of caffeine in female handball players. A randomized, double-blind, placebo-controlled crossover design is used to minimize inter-individual variability and improve internal validity. Participants complete three experimental conditions (placebo, low-dose caffeine, and moderate-dose caffeine), each separated by an adequate washout period to reduce potential carryover effects.

The protocol includes standardized procedures to control for confounding factors such as time of day, environmental conditions, and prior physical activity. Testing sessions follow a fixed sequence, beginning with cognitive assessment, followed by a sport-specific throwing task, and concluding with an intermittent running test. This structure is designed to reflect the multi-component demands of team sport performance while maintaining methodological control.

The primary objective is to determine whether caffeine produces dose-dependent effects across different performance domains. Specifically, the study examines whether physical performance improvements occur at lower doses, whether cognitive performance shows greater sensitivity to higher doses, and whether technical motor performance responds differently to caffeine ingestion. By integrating these domains within a single experimental design, the study aims to provide a more ecologically valid understanding of caffeine's ergogenic effects in team sport contexts.

The findings are expected to contribute to evidence-based recommendations for caffeine use in athletes, emphasizing the importance of aligning supplementation strategies with specific performance goals rather than assuming uniform benefits across all domains.

Studietype

Intervensjonell

Registrering (Faktiske)

20

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Central
      • Sinop, Central, Tyrkia (Türkiye), 57100
        • Sinop University

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen

Tar imot friske frivillige

Ja

Beskrivelse

Inclusion Criteria:

  • Female handball players
  • Regular participation in competitive handball training
  • Minimum of 3 years of handball training experience
  • Free from musculoskeletal injury within the past 6 months

Exclusion Criteria:

  • Known caffeine sensitivity or allergy
  • Use of medications or supplements that may affect physical or cognitive performance
  • Presence of cardiovascular disease
  • Presence of metabolic disorders

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo Condition
Participants receive placebo capsules prior to testing in a randomized
Ingestion of identical capsules containing polydextrose with no active ingredient, administered 60 minutes prior to testing.
Eksperimentell: Low-Dose Caffeine
Participants receive 3 mg/kg caffeine prior to testing in a randomized
Acute ingestion of caffeine at a dose of 3 mg per kilogram of body mass, administered in capsule form 60 minutes prior to testing.
Eksperimentell: Moderate-Dose Caffeine
Participants receive 6 mg/kg caffeine prior to testing in a randomized
Acute ingestion of caffeine at a dose of 6 mg per kilogram of body mass, administered in capsule form 60 minutes prior to testing.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Flanker Task Reaction Time
Tidsramme: During each experimental session (60 minutes after supplementation)
Mean reaction time (ms) during correct trials in the Simplified Eriksen Flanker task, used to assess cognitive processing speed.
During each experimental session (60 minutes after supplementation)
Yo-Yo Intermittent Recovery Test Level 1 Distance
Tidsramme: During each experimental session (60 minutes after supplementation)
Total distance covered during the Yo-Yo Intermittent Recovery Test Level 1, used to assess intermittent running performance.
During each experimental session (60 minutes after supplementation)
Throwing Velocity
Tidsramme: During each experimental session (60 minutes after supplementation)
Mean ball velocity (km/h) measured during a standardized handball throwing test.
During each experimental session (60 minutes after supplementation)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Flanker Task Accuracy
Tidsramme: During each experimental session (60 minutes after supplementation)
Percentage of correct responses in the Simplified Eriksen Flanker task.
During each experimental session (60 minutes after supplementation)
Flanker Effect
Tidsramme: During each experimental session (60 minutes after supplementation)
Difference in reaction time between incongruent and congruent trials in the Flanker task.
During each experimental session (60 minutes after supplementation)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

25. januar 2026

Primær fullføring (Faktiske)

10. mars 2026

Studiet fullført (Faktiske)

20. mars 2026

Datoer for studieregistrering

Først innsendt

24. april 2026

Først innsendt som oppfylte QC-kriteriene

24. april 2026

Først lagt ut (Faktiske)

1. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

1. mai 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

24. april 2026

Sist bekreftet

1. april 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

IPD-planbeskrivelse

At the time of registration, a decision regarding sharing individual participant data (IPD) has not yet been finalized. The study dataset is currently being prepared for publication and institutional archiving. Future data sharing will be considered after publication, taking into account institutional policies, ethical approvals, and participant confidentiality requirements. If appropriate, de-identified data underlying the published results may be made available upon reasonable request.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere